Other (Income)/Deductions—Net - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 30, 2025	Mar. 31, 2024
Loss Contingencies [Line Items]
Net (gains) losses recognized during the period on equity securities	[1],[2]	$ 370	$ (25)
Net unrealized losses	[3]	(1,295)	(188)
Intangible asset impairment charge		224
License [Member] | Biopharma [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge		210
Haleon [Member]
Loss Contingencies [Line Items]
Net (gains) losses recognized during the period on equity securities		144
Net unrealized losses		1,000
Gain on sale of equity method investment		$ 900	$ 150

[1] The net losses in the first quarter of 2025 include, among other things, a net loss of $144 million related to our investment in Haleon, composed of unrealized losses of $1.0 billion, partially offset by $900 million in realized gains on the sales of our remaining investment.

[2] Reported in Other (income)/deductions––net. See Note 4.

[3] Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of March 30, 2025, there were cumulative impairments and downward adjustments of $400 million and upward adjustments of $223 million. Impairments, downward and upward adjustments were not material to our operations in the first quarters of 2025 and 2024.